Skip to main content
Top
Published in: Endocrine 2/2010

01-10-2010 | Original Article

Anti-Saccaromyces Cerevisiae antibodies (ASCA) are elevated in autoimmune thyroid disease ASCA in autoimmune thyroid disease

Authors: Dilek Yazıcı, Sibel Zehra Aydın, Dilek Yavuz, Özlem Tarçın, Oğuzhan Deyneli, Haner Direskeneli, Sema Akalın

Published in: Endocrine | Issue 2/2010

Login to get access

Abstract

Environmental factors have been implicated in the development of autoimmune thyroid disease (AITD). Anti-Saccaromyces Cerevisiae Antibodies (ASCA) were shown to be elevated in several autoimmune diseases. The aim of the study was to determine ASCA levels and their relationship with thyroid autoantibodies in patients with AITD. One-hundred and twelve patients with AITD (age 41.1 ± 12.8 years; F/M:96/16) and 103 healthy controls (38.5 ± 10.3 years; F/M:82/21) were included. Twenty-four patients had Graves disease (GD), and 88 had Hashimoto’s thyroiditis (HT). ASCA IgA and IgG, TSH, free T4, anti-thyroglobulin, and anti-thyroid peroxidase antibody concentrations were determined. ASCA IgA positivity in patients with GD (16.6%) was similar to patients with HT (13.6%) and was higher than controls (5.8%). No significant difference was present between the frequencies of IgG positivity among GD (12.5%), HT (7.9%), and control groups (5.8%). The mean levels of ASCA IgA and IgG were comparable within the groups. No correlation of ASCA and anti-thyroglobulin and anti-thyroid peroxidase levels was observed. Increased IgA ASCA positivity is observed in patients with GD, suggesting a role of environmental stimuli in its pathogenesis. The role of ASCA in the etiology of AITD needs to be further examined.
Literature
5.
go back to reference P. Heyma, L.C. Harrison, R. Robins-Browne, Clin. Exp. Immunol. 64, 249–254 (1986)PubMed P. Heyma, L.C. Harrison, R. Robins-Browne, Clin. Exp. Immunol. 64, 249–254 (1986)PubMed
7.
go back to reference J.F. Quinton, B. Sendid, D. Reumaux, P. Duthilleul, A. Cortot, B. Grandbastien, G. Charrier, S.R. Targan, J.F. Colombel, D. Poulain, Gut 42, 788–791 (1998)CrossRefPubMed J.F. Quinton, B. Sendid, D. Reumaux, P. Duthilleul, A. Cortot, B. Grandbastien, G. Charrier, S.R. Targan, J.F. Colombel, D. Poulain, Gut 42, 788–791 (1998)CrossRefPubMed
8.
go back to reference R.K. Linskens, R.C. Mallant-Hent, Z.M. Groothuismink, L.E. Bakker-Jonges, J.P. van de Merwe, H. Hooijkaas, B.M. von Blomberg, S.G. Meuwissen, Eur. J. Gastroenterol. Hepatol. 14, 1013–1018 (2002)CrossRefPubMed R.K. Linskens, R.C. Mallant-Hent, Z.M. Groothuismink, L.E. Bakker-Jonges, J.P. van de Merwe, H. Hooijkaas, B.M. von Blomberg, S.G. Meuwissen, Eur. J. Gastroenterol. Hepatol. 14, 1013–1018 (2002)CrossRefPubMed
9.
go back to reference R.Ch. Mallant-Hent, B. Mary, E. von Blomberg, Z. Yüksel, P.J. Wahab, C. Gundy, G.A. Meyer, C.J. Mulder, Eur. J. Gastroenterol. Hepatol. 18, 75–78 (2006)CrossRefPubMed R.Ch. Mallant-Hent, B. Mary, E. von Blomberg, Z. Yüksel, P.J. Wahab, C. Gundy, G.A. Meyer, C.J. Mulder, Eur. J. Gastroenterol. Hepatol. 18, 75–78 (2006)CrossRefPubMed
10.
12.
go back to reference I. Krause, Y. Monselise, G. Milo, A. Weinberger, Clin. Exp. Rheumatol. 20, S21–S24 (2002)PubMed I. Krause, Y. Monselise, G. Milo, A. Weinberger, Clin. Exp. Rheumatol. 20, S21–S24 (2002)PubMed
13.
go back to reference S.Z. Aydin, P. Atagunduz, M. Temel, M. Bicakcigil, D. Tasan, H. Direskeneli, Rheumatology (Oxford) 47, 142–144 (2008)CrossRef S.Z. Aydin, P. Atagunduz, M. Temel, M. Bicakcigil, D. Tasan, H. Direskeneli, Rheumatology (Oxford) 47, 142–144 (2008)CrossRef
14.
go back to reference P.M. Theiss, L.M. da Silva Kotze, S.R. da Rosa Utiyama, R.M. Nisihara, I.G. Silva, P.G. Kotze, M. Olandoski, J. Clin. Gastroenterol. 44, 309–310 (2010)CrossRefPubMed P.M. Theiss, L.M. da Silva Kotze, S.R. da Rosa Utiyama, R.M. Nisihara, I.G. Silva, P.G. Kotze, M. Olandoski, J. Clin. Gastroenterol. 44, 309–310 (2010)CrossRefPubMed
16.
go back to reference G.R. Barclay, H. McKenzie, J. Pennington, D. Parratt, C.R. Pennington, R. Scand, J. Gastroenterol. 27, 196–200 (1992) G.R. Barclay, H. McKenzie, J. Pennington, D. Parratt, C.R. Pennington, R. Scand, J. Gastroenterol. 27, 196–200 (1992)
17.
go back to reference C.M. Mpofu, B.J. Campbell, S. Subramanian, S. Marshall-Clarke, C.A. Hart, A. Cross, C.I. Roberts, A. McGoldrick, S.W. Edwards, J.M. Rhodes, Gastroenterology 133, 1487–1498 (2007)CrossRefPubMed C.M. Mpofu, B.J. Campbell, S. Subramanian, S. Marshall-Clarke, C.A. Hart, A. Cross, C.I. Roberts, A. McGoldrick, S.W. Edwards, J.M. Rhodes, Gastroenterology 133, 1487–1498 (2007)CrossRefPubMed
18.
19.
go back to reference I. Fresko, V. Hamuryudan, M. Demir, N. Hizli, H. Sayman, M. Melikoglu, R. Tunc, S. Yurdakul, H. Yazici Ann, Rheum. Dis. 60, 65–66 (2001)CrossRef I. Fresko, V. Hamuryudan, M. Demir, N. Hizli, H. Sayman, M. Melikoglu, R. Tunc, S. Yurdakul, H. Yazici Ann, Rheum. Dis. 60, 65–66 (2001)CrossRef
20.
go back to reference T. Watts, I. Berti, A. Sapone, T. Gerarduzzi, T. Not, R. Zielke, A. Fasano, Proc. Natl. Acad. Sci. 102, 2916–2921 (2005)CrossRefPubMed T. Watts, I. Berti, A. Sapone, T. Gerarduzzi, T. Not, R. Zielke, A. Fasano, Proc. Natl. Acad. Sci. 102, 2916–2921 (2005)CrossRefPubMed
22.
go back to reference G.D. Chazenbalk, P.N. Pichurin, J. Guo, B. Papoport, S.M. McLachlan, Clin. Exp. Immunol. 139, 216–224 (2004)CrossRef G.D. Chazenbalk, P.N. Pichurin, J. Guo, B. Papoport, S.M. McLachlan, Clin. Exp. Immunol. 139, 216–224 (2004)CrossRef
23.
go back to reference C.M. Sorensen, T.K. Hansen, R. Steffensen, J.C. Jensenius, S. Thiel, Clin. Exp. Immunol. 145, 173–182 (2006)CrossRefPubMed C.M. Sorensen, T.K. Hansen, R. Steffensen, J.C. Jensenius, S. Thiel, Clin. Exp. Immunol. 145, 173–182 (2006)CrossRefPubMed
24.
go back to reference U. Monsén, J. Sorstad, G. Hellers, C. Johansson, Am. J. Gastroenterol. 85, 711–716 (1990)PubMed U. Monsén, J. Sorstad, G. Hellers, C. Johansson, Am. J. Gastroenterol. 85, 711–716 (1990)PubMed
25.
go back to reference J.A. Snook, H.J. de Silva, D.P. Jewell, Q. J. Med. 72, 835–840 (1989)PubMed J.A. Snook, H.J. de Silva, D.P. Jewell, Q. J. Med. 72, 835–840 (1989)PubMed
26.
go back to reference T. Inokuchi, Y. Moriwaki, S. Takahashi, Z. Tsutsumi, T. Ka, T. Yamamoto, Intern. Med. 44, 303–306 (2005)CrossRefPubMed T. Inokuchi, Y. Moriwaki, S. Takahashi, Z. Tsutsumi, T. Ka, T. Yamamoto, Intern. Med. 44, 303–306 (2005)CrossRefPubMed
27.
go back to reference S.A. Shah, M.A. Peppercorn, J.A. Pallotta, Am. J. Gastroenterol. 96, 1925–1926 (2001)CrossRef S.A. Shah, M.A. Peppercorn, J.A. Pallotta, Am. J. Gastroenterol. 96, 1925–1926 (2001)CrossRef
Metadata
Title
Anti-Saccaromyces Cerevisiae antibodies (ASCA) are elevated in autoimmune thyroid disease ASCA in autoimmune thyroid disease
Authors
Dilek Yazıcı
Sibel Zehra Aydın
Dilek Yavuz
Özlem Tarçın
Oğuzhan Deyneli
Haner Direskeneli
Sema Akalın
Publication date
01-10-2010
Publisher
Springer US
Published in
Endocrine / Issue 2/2010
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-010-9372-y

Other articles of this Issue 2/2010

Endocrine 2/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine